ROVI reports the financial results obtained in 2021, a historic year for the group in terms of the figures achieved and the capabilities it demonstrated to adapt to the needs of the pandemic.
ROVI achieved operating revenue growth of 54% compared to 2020. This result was mainly driven by the strength of the contract manufacturing organization business, which grew by 189% and by the specialty pharmaceutical business, where sales rose 17%.
Net profit totalled 153.1 million, 151% up on the preceding year. EBITDA rose by 115% to 202.9 million euros in 2021, reflecting a 8.8 percentage point increase in the EBITDA margin, which rose to 31.3% in 2021 from 22.4% in 2020.
Sales of prescription-based pharmaceutical products rose 17% to 347.2 million euros in 2021.
Juan López-Belmonte, Chairman and Chief Executive Officer of ROVI said that “the 2021 results are historic for ROVI and demonstrate our company’s ability to continuously adapt”.